Key result
Amlodipine showed no difference in mortality or MACE compared to other antihypertensives in high-risk patients, but decreased stroke risk across groups and increased CHF risk in diabetic patients.
Why the study?
Does amlodipine reduce cardiovascular events and blood pressure in hypertensive patients with diabetes and/or renal dysfunction compared to other antihypertensive medications?
Population
Hypertensive patients with either concomitant diabetes and/or renal dysfunction from 38 randomized…
Comparison
Amlodipine or other calcium channel blockers vs Other classes of antihypertensive medications
Design
Meta-analysis
Follow-up
≥6 months
Authors
Loading...
Supports amlodipine for stroke prevention in high-risk hypertension; extends Level 1 evidence on CHF risk in diabetes.
Meta-Analysis
Does amlodipine reduce cardiovascular events and blood pressure in hypertensive patients with diabetes and/or renal dysfunction compared to other antihypertensive medications?
Amlodipine is an effective antihypertensive option that reduces stroke risk in high-risk patients with diabetes or renal dysfunction, though it may increase the risk of heart failure in diabetic patients.
Jeffers et al. (2015) conducted a meta-analysis in Hypertension with concomitant diabetes mellitus and/or renal dysfunction. Amlodipine vs. Diuretics, β-blockers, α-blockers, ACE inhibitors, or ARBs was evaluated on Blood pressure and cardiovascular events (all-cause death, CV death, MI, stroke, CHF, or MACE). Amlodipine showed no difference in mortality or MACE compared to other antihypertensives in high-risk patients, but decreased stroke risk across groups and increased CHF risk in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: